Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

AstraZeneca and Fudan Univ. to Collaborate on Cardiovascular Disease

publication date: Dec 19, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
AstraZeneca will collaborate with Fudan University to discover the mechanism behind leonurine, a TCM product derived from Herba Leonuri that is used to treat heart disease, ischemic stroke and atherosclerosis. AstraZeneca will underwrite the cost of two years of research with the hope of discovering a new treatment for the diseases. More details....

Stock Symbol: (NYSE: AZN)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
ChinaBio Leadership Retreat 2014
Suzhou, China
October 23-24, 2014
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors